Extended Data Fig. 2: Intra-patient robustness of macrophage manufacturing process.
From: Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial
Three participants (P1, P2, P3) donated leukapheresis three times at monthly intervals and received infusions of freshly manufactured macrophages. a, The total leukocyte content and the b, CD14 content of each donation remained constant between each donation timepoint. c, CD14+ selection efficiency and d, conversion to macrophages in the final product remained constant between each donation and comparable to the main group (Extended Data Fig. 1). e, Accordingly, the participants received infusions of comparable numbers of macrophages on each occasion, even though the product was manufactured in a unique production run per product.
